Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 9, 22 | -0.40
Increased by
+63.30%
|
-0.48
Increased by
+16.67%
|
Aug 12, 22 | -0.96
Increased by
+3.03%
|
-0.78
Decreased by
-23.08%
|
May 12, 22 | -0.88
Increased by
+12.00%
|
-0.83
Decreased by
-6.02%
|
Mar 10, 22 | -1.04
Increased by
+1.89%
|
-1.25
Increased by
+16.80%
|
Nov 12, 21 | -1.09
Increased by
+18.05%
|
-1.16
Increased by
+6.03%
|
Aug 12, 21 | -0.99
Increased by
+22.05%
|
-1.13
Increased by
+12.39%
|
May 11, 21 | -1.00
Decreased by
-69.49%
|
-1.01
Increased by
+0.99%
|
Mar 18, 21 | -1.06
Increased by
+32.48%
|
-1.25
Increased by
+15.20%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-19.10 M
Increased by
+32.79%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-25.86 M
Decreased by
-0.11%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-23.12 M
Increased by
+4.38%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-27.16 M
Decreased by
-14.65%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-28.42 M
Increased by
+4.78%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-25.83 M
Increased by
+7.95%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-24.18 M
Decreased by
-95.48%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-23.69 M
Decreased by
-34.34%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.